ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1651

Prospective Cohort Study of Antibody-Guided Therapy in Patients with Membranous Nephropathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • van de Logt, Anne-Els, Radboud Universiteit, Nijmegen, Gelderland, Netherlands
  • Vink- van Setten, Coralien, Radboud Universiteit, Nijmegen, Gelderland, Netherlands
  • Wetzels, Jack F., Radboud Universiteit, Nijmegen, Gelderland, Netherlands

Guidelines advise a standard course of 6 months of cyclophosphamide (CP) and steroids in patients with membranous nephropathy (MN). We hypothesized that monitoring of aPLA2R- antibodies (aPLA2R) may enable individualized (and shorter duration of) therapy.


Patients with MN, with positive aPLA2R and high risk of progression were included. Treatment consisted of CP (1.5 mg/kg/day combined with steroids). aPLA2R were monitored (IFT test) at 8, 16, and 24 weeks after start of treatment. If the IFT test was negative, CP was stopped and prednisone tapered. If the IFT test remained positive at 24 weeks, CP was switched to MMF and therapy continued.


Sixty-five patients (48 males) were included; mean age 61 ± 12 yrs, median serum creatinine 136 [IQR 100-161] µmol/l, serum albumin 21 [IQR 16-26] g/l and UPCR 7.7 [IQR 5.4-11.1] g/10 mmol. Follow-up was 37 [IQR 27-58] months. aPLA2R test was negative in 46 patients after 8 weeks (group A), in 10 patients after 16 weeks (group B1), in 1 patient after 24 weeks (group B2) and in 8 patients aPLA2R remained positive after more than 24 weeks (group B3). In group A no clinical remission (PCR >3.0 g/10 mmol) was observed in 26 % (12 patients) compared to 21 % (4 patients) in group B1-B3 (Log rank p=0.579). Overall 22 patients (34 %) received additional immunosuppressive (IS) therapy because of persistent proteinuria (after aPLA2R disappearance) or clinical relapse. IS free survival was lower in group A compared to group B1-B3. (Figure 1).


Approximately 50% of patients developed long-term clinical remission after 8 weeks of therapy. Our data support aPLA2R-guided therapy. However, in approximately 25% of patients immunological remission was not followed by clinical remission, underlining the need for better biomarkers.

Relapse or start of second immunosuppressive therapy


  • Other NIH Support